home / stock / aim / aim news

AIM News and Press, AIM ImmunoTech Inc. From 03/26/24

Stock Information
Company Name: AIM ImmunoTech Inc.
Stock Symbol: AIM
Market: NYSE
Website: aimimmuno.com
Menu
AIM AIM Quote AIM Short AIM News AIM Articles AIM Message Board
Get AIM Alerts

News, Short Squeeze, Breakout and More Instantly...
AIM - AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company’s Q4/FY2023 operational and financial...
AIM - AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

OCALA, Fla., March 25, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced the publication of new data analysis from a long-term Early Access Program (“EAP”) studying the company’s drug Ampligen® (rintatolim...

AIM - AIM ImmunoTech Announces Release of the Next CEO Corner Segment

OCALA, Fla., March 20, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Thomas Equels,...

AIM - AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity

OCALA, Fla., March 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that it will present at the Virtual Investor Lunch Break: The AIM Opportunity event on Wednesday, March 20, 2024 at 12:00 ...
AIM - AIM ImmunoTech Announces Launch of CEO Corner Platform

CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties the ability to ask questions and submit topics for future videos Access the AIM CEO Corner Here! OCALA, Fla., March 07, 2024...

AIM - AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update

Company continues progress across Ampligen ® clinical development programs Growing body of promising data demonstrates Ampligen’s potential to address multiple high-value indications OCALA, Fla., Feb. 29, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE...

AIM - AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer

OCALA, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the first subject has been dosed at Erasmus Medical Center (“Erasmus MC”) in a Phase 1b/2 clinical trial combining...
AIM - AI-Media's LEXI Tool Kit Expanded with LEXI Recorded - Breakthrough Solution for the Growing VOD Market

BROOKLYN, N.Y., Feb. 13, 2024 (GLOBE NEWSWIRE) -- AI-Media is excited to announce the launch of its VOD automated captioning solution, LEXI Recorded . This groundbreaking product, created initially for a major sporting franchise, utilizes the cutting-edge AI (Artificial Intelligence) tech...

AIM - AIM stock dips amid mixed results for post-COVID fatigue therapy

2024-02-08 11:37:46 ET More on Agios Pharmaceuticals, AIM ImmunoTech, etc. CVS Health Corporation (CVS) Q4 2023 Earnings Call Transcript CVS Health FY23 Earnings: Downgrades Inevitable, Long Term Outlook In The Balance CVS Health Corporation 2023 Q4 - Results - Earni...

AIM - AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions Safety results show Ampligen is generally well tolerated in the treatment of Post-COVID Conditions OCALA, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoT...
Previous 10 Next 10